Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (271-280 of 662) with videos related to

Pageof 67
Sort By:
European Journal of Immunology|August 19, 2009
The protein tyrosine kinase Tec regulates mast cell functionUwe Schmidt, Anastasia Abramova, Nicole Boucheron, et al.
Experimental Hematology|October 17, 2017
Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph<sup>+</sup> chronic myeloid leukemiaMichael Willmann, Irina Sadovnik, Gregor Eisenwort, et al.
Wiener Klinische Wochenschrift|November 26, 2014
10th anniversary of the Austrian MDS Platform: aims and ongoing projectsSonja Burgstaller, Peter Bettelheim, Otto Krieger, et al.
Cancers|December 24, 2021
Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid LeukemiaJavier Bregante, Anna Schönbichler, Daniel Pölöske, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5)Wolfgang R Sperr, Maria Piribauer, Friedrich Wimazal, et al.
European Journal of Clinical Investigation|October 10, 2013
Proposed score for survival of patients with myelodysplastic syndromesWolfgang R Sperr, Michael Kundi, Friedrich Wimazal, et al.
Journal of Cancer Research and Clinical Oncology|January 26, 2020
An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosisPhilipp Riffel, Juliana Schwaab, Christopher Lutz, et al.
Experimental Hematology|January 11, 2014
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRAIrina Sadovnik, Els Lierman, Barbara Peter, et al.
International Archives of Allergy and Immunology|June 18, 2002
Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of diseaseWolfgang R Sperr, John-Hendrik Jordan, Michael Fiegl, et al.
Haematologica|November 13, 2010
Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experiencePeter Schellongowski, Thomas Staudinger, Michael Kundi, et al.
Pageof 67

Showing results (271-280 of 662) with videos related to

Sort By:
Pageof 67
European Journal of Immunology|August 19, 2009
The protein tyrosine kinase Tec regulates mast cell functionUwe Schmidt, Anastasia Abramova, Nicole Boucheron, et al.
Experimental Hematology|October 17, 2017
Evaluation of cooperative antileukemic effects of nilotinib and vildagliptin in Ph<sup>+</sup> chronic myeloid leukemiaMichael Willmann, Irina Sadovnik, Gregor Eisenwort, et al.
Wiener Klinische Wochenschrift|November 26, 2014
10th anniversary of the Austrian MDS Platform: aims and ongoing projectsSonja Burgstaller, Peter Bettelheim, Otto Krieger, et al.
Cancers|December 24, 2021
Efficacy and Synergy of Small Molecule Inhibitors Targeting <i>FLT3</i>-ITD<sup>+</sup> Acute Myeloid LeukemiaJavier Bregante, Anna Schönbichler, Daniel Pölöske, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2004
A novel effective and safe consolidation for patients over 60 years with acute myeloid leukemia: intermediate dose cytarabine (2 x 1 g/m2 on days 1, 3, and 5)Wolfgang R Sperr, Maria Piribauer, Friedrich Wimazal, et al.
European Journal of Clinical Investigation|October 10, 2013
Proposed score for survival of patients with myelodysplastic syndromesWolfgang R Sperr, Michael Kundi, Friedrich Wimazal, et al.
Journal of Cancer Research and Clinical Oncology|January 26, 2020
An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosisPhilipp Riffel, Juliana Schwaab, Christopher Lutz, et al.
Experimental Hematology|January 11, 2014
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRAIrina Sadovnik, Els Lierman, Barbara Peter, et al.
International Archives of Allergy and Immunology|June 18, 2002
Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of diseaseWolfgang R Sperr, John-Hendrik Jordan, Michael Fiegl, et al.
Haematologica|November 13, 2010
Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: a single center experiencePeter Schellongowski, Thomas Staudinger, Michael Kundi, et al.
Pageof 67